March 18th, 2021

Dr. Brett Gershman, post-doctoral research associate at VaxForm, will present some of our work on COVID-19 vaccine development at the NFID Virtual 2021 Annual Conference on Vaccinology Research (ACVR) taking place April 26-27, 2021. His Abstract titled “Development of a recombinant protein subunit vaccine against COVID-19 with a novel adjuvant system to induce a balanced Th1/Th2 immune response" was selected for an oral presentation. 

Dr. Garry Morefield, President of VaxForm, was featured on WDIY, Lehigh Valley public radio. Listen to the recording to learn more about VaxForm and hear an update on our efforts to develop an oral COVID-19 vaccine. 

 OraSure's Dr. Stephen Tang & VaxForm's Dr. Garry Morefield | Teen Scientist | WDIY 

VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to support the development of their oral COVID-19 vaccine candidate.

 Awardees phase 1 details | NSF SBIR 

VaxForm is awarded $300,000 from the PA Department of Community and Economic Development to support the development of their oral COVID-19 vaccine candidate.

Wolf Administration Awards $10 Million to 23 Entities to Develop Effective COVID-19 Vaccines, Treatments and Therapies - PA Department of Community & Economic Development 

VaxForm is awarded a Phase I SBIR grant from the National Science Foundation (NSF) to further develop their oral vaccine delivery platform. The project is entitled: "Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphtheria Tetanus Pertussis vaccine."

 SBIR Phase I: Incorporation of a new adjuvant system to produce a thermally stable, orally administered Diphteria-Tetanus-Pertussis vaccine | SBIR.gov 

VaxForm publishes their latest results from the pre-clinical development of their recombinant fusion protein vaccine targeting Streptococcus Pyogenes bacteria in AAPS Journal. The vaccine successfully induced neutralizing antibodies in mice and displayed robust stability.

 Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes - PubMed (nih.gov)  

VaxForm publishes the results of the non-clinical safety studies of their vaccine candidate for Streptococcus Pyogenes. Rabbits were administered the maximum anticipated dose of the vaccine and exhibited no significant adverse reaction events. This is a great milestone achievement towards the initiation of first-in-human clinical trial of the vaccine. 

 Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant - PubMed (nih.gov)